TXN and neoplasm: Considering that thioredoxin is the main target of GA and thioredoxin is tightly negatively associated with intracellular ROS level and cell ferroptosis (Figure 2B), the intracellular thioredoxin level in tumor cells after NP‐G/P+H treatment was first determined.[26] The results revealed that NP‐G/P treatment could significantly deplete thioredoxin in 4T1 cells by 39.3% while HIFU and NP‐G/P+H treatments sharply deplete thioredoxin in cells by 83.7% and 84.4%, respectively compared to PBS treatment (Figure 4E).